However, unlike the CLL1-degrader conjugate, ROR1 DAC treatment significantly inhibits tumor growth with continuous dosing, potentially due to the modest cytotoxicity and sustained degradation requirements of MZ1. Here, ROR1 is linked to neoplasm.